Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $168.2 million.

  • Avidity Biosciences' Non-Current Assets rose 78966.94% to $168.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.3 million, marking a year-over-year increase of 36291.01%. This contributed to the annual value of $21.6 million for FY2024, which is 2526.09% up from last year.
  • Avidity Biosciences' Non-Current Assets amounted to $168.2 million in Q3 2025, which was up 78966.94% from $118.4 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Non-Current Assets registered a high of $168.2 million during Q3 2025, and its lowest value of $2.8 million during Q1 2021.
  • Over the past 5 years, Avidity Biosciences' median Non-Current Assets value was $16.8 million (recorded in 2023), while the average stood at $28.7 million.
  • In the last 5 years, Avidity Biosciences' Non-Current Assets crashed by 353.43% in 2022 and then surged by 78966.94% in 2025.
  • Over the past 5 years, Avidity Biosciences' Non-Current Assets (Quarter) stood at $16.4 million in 2021, then dropped by 3.53% to $15.9 million in 2022, then increased by 8.77% to $17.2 million in 2023, then grew by 25.26% to $21.6 million in 2024, then soared by 678.49% to $168.2 million in 2025.
  • Its last three reported values are $168.2 million in Q3 2025, $118.4 million for Q2 2025, and $24.1 million during Q1 2025.